Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 7Head & Neck 2Gastrointestinal 2Gynecologic 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Head and Neck Neoplasms 19Squamous Cell Carcinoma of Head and Neck 11Carcinoma, Non-Small-Cell Lung 8Lung Neoplasms 6Neoplasms 4Melanoma 4Laryngeal Diseases 4Carcinoma 3Stomach Neoplasms 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Neoplasms, Squamous Cell 2Neoplasms by Site 2Neoplasms by Histologic Type 2Hypopharyngeal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Breast Neoplasms 2Thyroid Neoplasms 1Thyroid Diseases 1Thyroid Carcinoma, Anaplastic 1Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1

Interventions

Cisplatin 4pembrolizumab 3selpercatinib 2pralsetinib 2Pemetrexed 2Paclitaxel 2Fulvestrant 2Carboplatin 2trametinib 1ribociclib 1repotrectinib 1patritumab 1palbociclib 1golotimod 1exemestane 1dabrafenib 1cobimetinib 1alectinib 1abemaciclib 1Vemurafenib 1Taxes 1Tamoxifen 1STX-478 1Radiotherapy, Intensity-Modulated 1Nimorazole 1Metformin 1Letrozole 1Imlunestrant 1Gemcitabine 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms by Site × Pemetrexed × Head & Neck × Clear all
NCT04222972 2026-03-05

AcceleRET-Lung

Hoffmann-La Roche

Phase 3 Terminated
223 enrolled 18 charts
Head & NeckThoracic

Adenocarcinoma, Bronchial Diseases, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

Phase 1/2 Active not recruiting
296 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡